A REVIEW ON RECENT ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS OF TAMSULOSIN
DOI:
https://doi.org/10.22159/ijap.2024v16i2.49950Keywords:
Tamsulosin, Skin, Transdermal, Matrix system, Reservoir system, NanotransfersomesAbstract
Tamsulosin is a highly selective α1-adrenoreceptor antagonist. It has been developed to treat signs and symptoms of benign prostatic hyperplasia. Tamsulosin is absorbed quickly and completely in intestinal mucosa and is eliminated gradually after oral administration, which might generate some side effects as postural hypotension in number of patients. Transdermal drug delivery systems were developed for prolonged tamsulosin delivery in order to control its bioavailability and minimize its side effects. Hence, the present review aims to discuss thoroughly the various transdermal drug delivery systems of tamsulosin investigated in recent years. This review also discusses the skin as a route of drug administration, technologies in transdermal drug delivery along with different techniques used in the preparation of transdermal delivery systems of tamsulosin and their effects on its release and permeation.
Downloads
References
Retnayyan A, Sreedharan S, Rethinaswamy FP, Narayan Nampoothiri HK, Mathew B. Comparison of efficacy of tamsulosin, alfuzosin, and silodosin in the management of benign prostatic hyperplasia. Asian J Pharm Clin Res. 2023;16:138-42. doi: 10.22159/ajpcr.2023.v16i2.46439.
USP pharmacopeia; 2005.
Siddartha B, Sudheer BI, Ravichandra GC, Parthiban C. Analytical method development and validation for simultaneous estimation of tamsulosin and tolterdoine in bulk and pharmaceutical dosage form by rp-hplc method. Asian J Pharm Clin Res. 2014 Apr 1;7(2):156-60.
Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K, Ward J. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica. 1996;26(6):637-45. doi: 10.3109/00498259609046739, PMID 8810034.
Franco-Salinas G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet. 2010 Mar;49(3):177-88. doi: 10.2165/11317580-000000000-00000, PMID 20170206.
Narayan P, Tunuguntla HS. Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol. 2005;7Suppl 4:S42-8. PMID 16986054.
Lowe FC. Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7Suppl 4:S13-21. PMID 16986050.
Shrivastava A, Saxena P, Gupta VB. Spectrophotometric estimation of tamsulosin hydrochloride by acid-dye method. Pharm Methods. 2011;2(1):53-60. doi: 10.4103/2229-4708.81089, PMID 23781431.
Reddy KGS, Kumar AS, Debnath M, Kumar RV. Stability indicating rp-hplc method development and validation for simultaneous determination of dutasteride and tamsulosin in bulk as well as in pharmaceutical dosage form by using pda detector. Asian J Pharm Clin Res. 2014;7:105-13.
Neill MG, Shahani R, Zlotta AR. Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Ther Clin Risk Manag. 2008;4(1):11-8. doi: 10.2147/tcrm.s86, PMID 18728700.
Kumar MA, Lakshmi DPK, Balasubramanium DJ. Formulation development and in vitro evaluation of tamsulosin Hcl extended-release pellets. Int J PharmTech Res. 2011;3(2):968-79.
Wang J, Sun Y, Li B, Fan R, Li B, Yin T. Preparation and evaluation of tamsulosin hydrochloride sustained-release pellets modified by two-layered membrane techniques. Asian J Pharm Sci. 2015;10(1):31-9. doi: 10.1016/j.ajps.2014.08.009.
Sachan R, Bajpai M. Transdermal drug delivery system: a review. Int J Res Dev Pharm Life Sci. 2013;3(1):748-65.
Valeveti SK, Pashikanti S. Design, development, and evaluation of transdermal patches containing memantine hydrochloride. Int J App Pharm. 2023;15:181-97. doi: 10.22159/ijap.2023v15i5.48481.
Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M. Microneedles: a smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother. 2019 Jan;109:1249-58. doi: 10.1016/j.biopha.2018.10.078, PMID 30551375.
https://my.clevelandclinic.org/Health/Body/21901-Epidermis. [Last assessed on 20 Nov 2023]
Supe SM, Takudage PJ. Methods for evaluating penetration of drug into the skin: a review. Skin Res Technol. 2021;27(3):299-308. doi: 10.1111/srt.12968, PMID 33095948.
Jhawat V, Kamboj S, Maggon N. Transdermal drug delivery systems: approaches and advancements in drug penetration through skin. Int J Pharm Sci Rev Res. 2013;20(1):47-56.
Souto EB, Fangueiro JF, Fernandes AR, Cano A, Sanchez-Lopez E, Garcia ML. Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. Heliyon. 2022 Feb 11;8(2):e08938. doi: 10.1016/j.heliyon.2022.e08938, PMID 35198788.
Iyer A, Jyothi VGSS, Agrawal A, Khatri DK, Srivastava S, Singh SB. Does skin permeation kinetics influence efficacy of topical dermal drug delivery system?: assessment, prediction, utilization, and integration of chitosan biomacromolecule for augmenting topical dermal drug delivery in skin. J Adv Pharm Technol Res. 2021 Oct-Dec;12(4):345-55. doi: 10.4103/japtr.japtr_82_21, PMID 34820308.
Kovacik A, Kopecna M, Vavrova K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert Opin Drug Deliv. 2020 Feb;17(2):145-55. doi: 10.1080/17425247.2020.1713087, PMID 31910342.
Kandavilli S, Nair VB, Panchagnula R. Polymers in transdermal drug delivery systems. Pharm Technol. 2002;26:62-80.
Phatale V, Vaiphei KK, Jha S, Patil D, Agrawal M, Alexander A. Overcoming skin barriers through advanced transdermal drug delivery approaches. J Control Release. 2022 Nov;351:361-80. doi: 10.1016/j.jconrel.2022.09.025, PMID 36169040.
Sabbagh F, Kim BS. Recent advances in polymeric transdermal drug delivery systems. J Control Release. 2022 Jan;341:132-46. doi: 10.1016/j.jconrel.2021.11.025, PMID 34813879.
Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: design and current approaches to painless drug delivery. Acta Pharm. 2019 Jun 1;69(2):197-215. doi: 10.2478/acph-2019-0016, PMID 31259729.
Nasrollahzadeh M, Ganji F, Taghizadeh SM, Vasheghani Farahani E, Mohiti Asli M. Drug in adhesive transdermal patch containing antibiotic-loaded solid lipid nanoparticles. J Biosci Bioeng. 2022 Nov;134(5):471-6. doi: 10.1016/j.jbiosc.2022.08.003, PMID 36151004.
Martins NI, Sousa MP, Custodio CA, Pinto VC, Sousa PJ, Minas G. Multilayered membranes with tuned well arrays to be used as regenerative patches. Acta Biomater. 2017 Jul 15;57:313-23. doi: 10.1016/j.actbio.2017.04.021, PMID 28438703.
Sguizzato M, Esposito E, Cortesi R. Lipid-based nanosystems as a tool to overcome skin barrier. Int J Mol Sci. 2021;22(15):8319. doi: 10.3390/ijms22158319, PMID 34361084.
Carita AC, Eloy JO, Chorilli M, Lee RJ, Leonardi GR. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem. 2018 Feb 13;25(5):606-35. doi: 10.2174/0929867324666171009120154, PMID 28990515.
Pola KK, Kumar Rada S. An overview on ultra deformable vesicular drug delivery systems in transdermal drug delivery. Int J App Pharm. 2023;15:28-34. doi: 10.22159/ijap.2023v15i3.46785.
Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: design and current approaches to painless drug delivery. Acta Pharm. 2019 Jun 1;69(2):197-215. doi: 10.2478/acph-2019-0016, PMID 31259729.
Vashishth R, Chuong MC, Duarte JC, Gharat Y, Kerr SG. Two sustained-release membranes used in formulating low strength testosterone reservoir transdermal patches. Curr Drug Deliv. 2024;21(3):438-50. doi: 10.2174/1567201820666230316115921, PMID 36927432.
Sabbagh F, Kim BS. Recent advances in polymeric transdermal drug delivery systems. J Control Release. 2022 Jan;341:132-46. doi: 10.1016/j.jconrel.2021.11.025, PMID 34813879.
Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Dev Ind Pharm. 2013 Jan;39(1):39-50. doi: 10.3109/03639045.2012.657643, PMID 22335586.
Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: design and current approaches to painless drug delivery. Acta Pharm. 2019 Jun 1;69(2):197-215. doi: 10.2478/acph-2019-0016, PMID 31259729.
Pan Y, Li ZH, Qian DW, Liu P, Zhang Y, Shang EX. [Effects of different penetration enhancers on pharmacokinetics of active components in Xiangfu Siwu transdermal patches]. Zhongguo Zhong Yao Za Zhi. 2016 Jan;41(2):294-302. doi: 10.4268/cjcmm20160221, PMID 28861976.
Vashishth R, Chuong MC, Duarte JC, Gharat Y, Kerr SG. Two sustained release membranes used in formulating low-strength testosterone reservoir transdermal patches. Curr Drug Deliv. 2024;21(3):438-50. doi: 10.2174/1567201820666230316115921, PMID 36927432.
Assaf SM, Ghanem AM, Alhaj SA, Khalil EA, Sallam AA. Formulation and evaluation of Eudragit® RL polymeric double layer films for prolonged-release transdermal delivery of tamsulosin hydrochloride. AAPS PharmSciTech. 2022 Jul 29;23(6):210. doi: 10.1208/s12249-022-02358-x, PMID 35902492.
Ma X, Audett J, Soni PL, Singh N, Bailey SE, Leandro S. Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use. Patent No US. 1998;5(843):472 A.
Kawahara K, Nakao K, Yamaki H. Tamsulosin-containing transdermal patch. Patent application number; 2009.
Singh P, Lee ES, Jain AK. Transdermal administration of tamsulosin, pub. No.: US 2010/0291186; 2009. p. A1.
Assaf SM, Sallam ASA, Ghanem AM. Design and evaluation of transdermal delivery system containing tamsulosin hydrochloride. Journal of Drug Delivery Science and Technology. 2019;51:524-34. doi: 10.1016/j.jddst.2019.03.023.
Almehmady AM, Elsisi AM. Development, optimization, and evaluation of tamsulosin nanotransfersomes to enhance its permeation and bioavailability. J Drug Deliv Sci Technol. 2020;57:101667. doi: 10.1016/j.jddst.2020.101667.
Published
How to Cite
Issue
Section
Copyright (c) 2024 AYA M. GHANEM
This work is licensed under a Creative Commons Attribution 4.0 International License.
